UK’s Cancer Drugs Fund gets £400 million boost for life-saving drugs
Thousands of cancer patients in England will get life-saving drugs thanks to an extra £400 million ($646 million) invested in the Cancer Drugs Fund. It was due to expire in 2014 but the additional funding will now see it extended until March 2016.
The fund was created in 2010 to enable patients who were prescribed expensive cancer drugs to take advantage of the treatments which would not be routinely available to them on the National Health Service (NHS). More than 34,000 patients have benefitted from the Fund.
The extra financing means that the Fund is confirmed for an extra two years. The extension will allow new patients to benefit and guarantee that those already receiving drugs will continue to get them. The new money means the amount committed will top £1 billion in total.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze